Endothelin Receptor

亜型選択性的な製品

シグナル伝達経路

Endothelin Receptorシグナル伝達経路

Endothelin Receptor製品

  • All (7)
  • Endothelin Receptor拮抗剤(7)
  • 新製品
製品コード 製品名称 製品説明 文献中Selleckの製品使用例 お客様のフィードバック
S3051 Bosentan Hydrate Bosentan (Ro 47-0203) is an endothelin (ET) receptor antagonist for ET-A and ET-B with Ki of 4.7 nM and 95 nM, respectively.
Cancer Sci, 2023, 114(2):640-653
Nat Commun, 2022, 13(1):6078
Cardiovasc Res, 2021, 117(5):1391-1401
S8051 Macitentan Macitentan is an orally active, non-peptide, dual ETA/ETB (endothelin) receptor antagonist with IC50 of 0.5 nM/391 nM.
Biomedicines, 2022, 10(3)629
Front Pharmacol, 2021, 12:740529
Front Med (Lausanne), 2021, 8:742436
S7883 BQ-123 BQ-123 is a selective endothelin A receptor (ETA) antagonist with IC50 of 7.3 nM. Phase 2.
Baghdad Science Journal, 2023, 20(5 Suppl.)
J Mol Cell Cardiol, 2022, 171:16-29
BioMed Research International, 2019-, 10.1155/2019/3851718
S1456 Zibotentan (ZD4054) Zibotentan (ZD4054) is a specific Endothelin (ET)A antagonist with IC50 of 21 nM, exhibiting no activity at ETB. Phase 3.
Cell Death Dis, 2023, 14(1):5
Hepatology, 2016, 63(3):1000-12
Oncotarget, 2016, 7(47):77138-77151
S2097 Ambrisentan Ambrisentan (LU-208075, BSF-208075) is a highly selective antagonist of the endothelin-1 type A receptor, used in the treatment of pulmonary arterial hypertension (PAH).
Eur J Pharmacol, 2019, 855:124-136
Pharmacol Res Perspect, 2017, 5(6)
S6665 Sparsentan (PS-433540, RE-021) Sparsentan (PS-433540, RE-021, DARA) is a dual endothelin type A receptor(ETA) and angiotensin II type 1 receptor antagonist.
Front Pharmacol, 2022, 13:964370
Biomedicines, 2021, 10(1)86
S0017 Lu-135252 Lu-135252 (Darusentan,HMR-4005) is a selective endothelin A receptor (ET-A receptor) antagonist indicated for the oral treatment of resistant hypertension.
S3051 Bosentan Hydrate Bosentan (Ro 47-0203) is an endothelin (ET) receptor antagonist for ET-A and ET-B with Ki of 4.7 nM and 95 nM, respectively.
Cancer Sci, 2023, 114(2):640-653
Nat Commun, 2022, 13(1):6078
Cardiovasc Res, 2021, 117(5):1391-1401
S8051 Macitentan Macitentan is an orally active, non-peptide, dual ETA/ETB (endothelin) receptor antagonist with IC50 of 0.5 nM/391 nM.
Biomedicines, 2022, 10(3)629
Front Pharmacol, 2021, 12:740529
Front Med (Lausanne), 2021, 8:742436
S7883 BQ-123 BQ-123 is a selective endothelin A receptor (ETA) antagonist with IC50 of 7.3 nM. Phase 2.
Baghdad Science Journal, 2023, 20(5 Suppl.)
J Mol Cell Cardiol, 2022, 171:16-29
BioMed Research International, 2019-, 10.1155/2019/3851718
S1456 Zibotentan (ZD4054) Zibotentan (ZD4054) is a specific Endothelin (ET)A antagonist with IC50 of 21 nM, exhibiting no activity at ETB. Phase 3.
Cell Death Dis, 2023, 14(1):5
Hepatology, 2016, 63(3):1000-12
Oncotarget, 2016, 7(47):77138-77151
S2097 Ambrisentan Ambrisentan (LU-208075, BSF-208075) is a highly selective antagonist of the endothelin-1 type A receptor, used in the treatment of pulmonary arterial hypertension (PAH).
Eur J Pharmacol, 2019, 855:124-136
Pharmacol Res Perspect, 2017, 5(6)
S6665 Sparsentan (PS-433540, RE-021) Sparsentan (PS-433540, RE-021, DARA) is a dual endothelin type A receptor(ETA) and angiotensin II type 1 receptor antagonist.
Front Pharmacol, 2022, 13:964370
Biomedicines, 2021, 10(1)86
S0017 Lu-135252 Lu-135252 (Darusentan,HMR-4005) is a selective endothelin A receptor (ET-A receptor) antagonist indicated for the oral treatment of resistant hypertension.

Endothelin Receptor阻害剤の選択性比較

Tags: Endothelin Receptor inhibitor|Endothelin Receptor agonist|Endothelin Receptor activator|Endothelin Receptor inducer|Endothelin Receptor antagonist|Endothelin Receptor signaling pathway|Endothelin Receptor assay kit